Search research articles
Contact Us
Filters
Showing results (631-640 of 869) with videos related to
Page
of 87
Sort By:
Science Advances
|
June 5, 2021
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Jiye Liu, Teru Hideshima, Lijie Xing, et al.
Blood
|
February 3, 2026
Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma
Ting Du, Teng Fang, Sindhu C Pillai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2006
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321
Bart Barlogie, Robert A Kyle, Kenneth C Anderson, et al.
Plos One
|
December 3, 2015
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells
Rikio Suzuki, Shohei Kikuchi, Takeshi Harada, et al.
Blood
|
April 17, 2010
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
Rao H Prabhala, Dheeraj Pelluru, Mariateresa Fulciniti, et al.
British Journal of Haematology
|
March 25, 2010
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
Kihyun Kim, Sun-Young Kong, Mariateresa Fulciniti, et al.
Haematologica
|
February 1, 2024
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
Paul G Richardson, Aurore Perrot, Jesus San Miguel, et al.
Blood Cancer Discovery
|
September 27, 2021
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation
Annamaria Gulla, Eugenio Morelli, Mehmet K Samur, et al.
The Lancet. Oncology
|
February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
Paul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Blood
|
February 8, 2007
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia
Anne-Sophie Moreau, Xiaoying Jia, Hai T Ngo, et al.
Page
of 87
Search research articles
Search
Showing results (631-640 of 869) with videos related to
Sort By:
Page
of 87
Science Advances
|
June 5, 2021
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Jiye Liu, Teru Hideshima, Lijie Xing, et al.
Blood
|
February 3, 2026
Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma
Ting Du, Teng Fang, Sindhu C Pillai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2006
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321
Bart Barlogie, Robert A Kyle, Kenneth C Anderson, et al.
Plos One
|
December 3, 2015
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells
Rikio Suzuki, Shohei Kikuchi, Takeshi Harada, et al.
Blood
|
April 17, 2010
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
Rao H Prabhala, Dheeraj Pelluru, Mariateresa Fulciniti, et al.
British Journal of Haematology
|
March 25, 2010
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
Kihyun Kim, Sun-Young Kong, Mariateresa Fulciniti, et al.
Haematologica
|
February 1, 2024
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
Paul G Richardson, Aurore Perrot, Jesus San Miguel, et al.
Blood Cancer Discovery
|
September 27, 2021
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation
Annamaria Gulla, Eugenio Morelli, Mehmet K Samur, et al.
The Lancet. Oncology
|
February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
Paul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Blood
|
February 8, 2007
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia
Anne-Sophie Moreau, Xiaoying Jia, Hai T Ngo, et al.
Page
of 87